- Home
- AVIR vs AMRN Comparison
AVIR vs AMRN Comparison
Compare AVIR & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | AMRN |
|---|---|---|
| Founded | 2012 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.3M | 342.8M |
| IPO Year | 2020 | 1998 |
Fundamental Metrics
Financial Performance| Metric | AVIR | AMRN |
|---|---|---|
| Price | $5.47 | $13.95 |
| Analyst Decision | Buy | Strong Sell |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 286.5K | 74.0K |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.00 | ★ 55.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $351,367,000.00 | $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $2.78 | $12.96 |
| 52 Week High | $6.45 | $20.90 |
Technical Indicators
Market Signals| Indicator | AVIR | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 65.57 | 53.76 |
| Support Level | $5.13 | $13.51 |
| Resistance Level | $5.83 | $14.55 |
| Average True Range (ATR) | 0.25 | 0.37 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 92.78 | 42.21 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.